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1. INTRODUCTION 
An impurity in a drug substance as defined by the international conference on 
Harmonization (ICH) Guidelines[1] is any component of the drug substance that is not 
the chemical entity defined as the drug substance and affects the purity of active 
ingredient or drug product [2]. Therefore any extraneous material present in the drug 
substance has to be considered an impurity even if it is totally inert or has superior 
pharmacological properties. The impurity profile of pharmaceuticals is of increasing 
importance as drug safety receives more and more attention from the public and from 
the media. Several recent books [3,4] and journal reviews[5] address this topic and 
guidelines are available from US and international authorities. Most active 
pharmaceutical ingredients (API) are produced by organic chemical synthesis. 
Various components, including residual solvents, trace amounts of inorganic, and 
organic components can be generated during such a process. Those components 
remaining in the final API are considered as impurities. The sources and routes of 
formation of impurities in generics are starting materials, by products and residual 
solvents from the API synthesis; degradants formed during the process and long term 
storage; contaminants from packaging components and other drug products 
manufactured in the same facility. Impurities could be forming from the impact of 
heat, light, and oxidants (including air) on the drug product and might be catalyzed or 
accelerated by trace metal impurities, changes in the pH of the formulation 
interactions with packaging components, excipients and other active ingredients, in 
the case of combination products. Therefore, identification, quantification, and control 
of impurities in the drug substance and drug product, are an important part of drug 
development and regulatory assessment. 
1.1. Classification of impurities 
Impurities in drug substance can be classified into the following categories[4] 
¾ Organic Impurities 
Organic impurities can arise during the manufacturing process and / or storage 
of the drug substance. They can be identified or unidentified, volatile, voltaic or 
nonvolatile 
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¾ Starting materials or intermediates 
These are the most common impurities found in every API unless a proper 
care is taken in every step involved throughout the multi-step synthesis. Although the 
end products are always washed with solvents, there are always chances of having the 
residual unreacted starting materials may remain unless the manufacturers are very 
careful about the impurities. 
¾ Degradation products 
Impurities can also be formed by degradation of the end product during 
manufacturing of bulk drugs. However, degradation products resulting from storage, 
formulation to different dosage forms and aging are common impurities in the 
medicines. 
¾  Reagents, ligands, and catalysts 
These chemicals are less commonly found in APIs; however, in some cases 
they may pose a problem as impurities. 
¾ Enantiomeric impurities 
The single enantiomeric form of a chiral drug is now considered as an 
improved chemical entity that may offer a better pharmacological profile and an 
increased therapeutic index with a more favorable adverse reaction. 
¾ Inorganic impurities  
Inorganic impurities may also derive from the manufacturing processes used 
for bulk drugs. They are normally known and identified and include the following  
¾ Reagents, ligands, and catalysts 
The chances of having these impurities are rare: however, in some processes, 
these could create a problem unless the manufacturers take proper care during 
production.  
¾ Heavy metals 
The main sources of heavy metals are the water used in the processes and the 
reactors (if stainless steel reactors are used) where acidification or acid hydrolysis 
takes place. These impurities of heavy metals can easily be avoided using 
demineralized water and glass-lined reactors 
¾ Other materials (eg.filter aids, charcoal) 
 
The filters or filtering aids such as centrifuge bags are routinely used in the 
bulk drugs manufacturing plants, and, in many cases, activated carbon is also used 
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The regular monitoring of fibers and black particles in the bulk drugs is essential to 
avoid these contaminations.  
¾ Organic volatile impurities 
Organic volatile impurities relates to residual solvents that may be found in the 
drug substance. 
¾ Method related 
During the production process of bulk active pharmaceutical ingredients, 
many opportunities for the generation of impurities may arise. In cases such as this, 
the impurities often result from “primary” impurities in raw materials, which are 
carried through the manufacturing process.[6] 
¾ Environmental related 
The primary environmental factors that can reduce stability of drug so these 
impurities know as environmental related impurity include the following. 
¾ Exposures to adverse temperatures  
There are many APIs that are labile to heat or tropical temperatures. For 
example, vitamins as drug substances are very heat – sensitive and degradation 
frequently leads to loss of potency in vitamin products, especially in liquid 
formulations. 
¾ Light-especially UV light 
Several studies have reported that ergometrine as well as methyl ergometrine 
injection is unstable under tropical conditions such as light and heat, and a very low 
level of active ingredient was found in many field samples. 
¾ Humidity 
For hygroscopic products, humidity is considered detrimental to both bulk 
powder and formulated solid dosage forms. Aspirin and ranitidine are classical 
examples. 
¾ Dosage form factors related 
Due do the nature of dosage form these impurities formed. Fluocinonide 
Topical solution USP, 0.05% (Teva pharmaceuticals USA, Inc., Sellersville, 
Pennsylvania) in 60 mL bottles, was recalled in the United States because of 
degradation / impurities leading to sub-potency. In general, liquid dosage forms are 
very much susceptible to both degradation and microbiological contamination. In this 
regard, water content, Ph of the solution /suspension, compatibility of anions and 
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cations, mutual interactions of ingredients, and the primary container are critical 
factors.  
 
¾ Mutual interaction amongst ingredients 
 In this case impurities are formed due to mutual amongst ingredients in the 
formulation. Most vitamins are very labile and on aging they pose a problem of 
instability in different dosage forms, especially in liquid dosage forms. Because of 
mutual interaction, the presence of nicotinamide in a formulation containing 4 
vitamins (nicotinamide, pyridoxine, riboflavin, and thiamine) causes the degradation 
of thiamine to a sub-standard level within a 1-year shelf-life of vitamin B-complex 
injections.  
¾ Functional group-related typical degradation 
a) Hydrolysis 
Hydrolysis is a chemical reaction during which molecules of water (H2O) are 
split into hydrogen cations and hydroxide anions (OH) in the process of a chemical 
mechanism. Examples include benzylpenicillin, barbital, chloramphenicol, 
chlordiazepoxide, lincomycin, and oxazepam. 
b) Oxidative degradation 
The chemical process of removing electrons from an element or compound is 
known as oxidative degradation. Hydrocortisone, methotrexate, adinazolam, hydroxyl 
group directly bonded to an aromatic ring (e.g., phenol derivatives such as 
catecholamines and morphine), conjugated diens (e.g., vitaminA and unsaturated free 
fatty acids), heterocyclic aromatic rings, nitroso and nitrite derivatives, and aldehydes 
(e.g., flavorings) are all susceptible to oxidative degradation. 
c) Photolytic cleavage 
The chemical decomposition of matter due to absorption of incident light is 
known as photolytic cleavage. Pharmaceutical products are exposed to light while 
being manufactured as a solid or solution, packaged, held in pharmacy shops or 
hospitals pending use, or held by the consumer pending use, ergometrine, nifedipine, 
nitroprusside, riboflavin, and phenothiazines are very labile to photo – oxidation.  
1.2. Importance of impurity profiling in regulatory requirements 
There is an ever increasing interest in impurities present in API`s.Recently, 
not only purity prile but also impurity profile has become essential as per various 
regulatory requirements. In the pharmaceutical world, an impurity is considered as 
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any other organic material, besides the drug substance, or ingredients, arise out of 
synthesis or unwanted chemicals that remains with API`s. The impurity may be 
developed either during formulation, or upon aging of both API`s and formulated 
API`s medicines. A good illustration of this definition may be identification of 
impurity in API`s like 1-(1, 2, 3, 4, 5, 6, 7-hexahydro-s-indacen-4-yl)-3-4[-1-hydroxy-
1-methyl-ethyl)-furan-2-sulphonylurea using Multidisciplinary approach. The 
presence of these unwanted chemicals, even in small amount, may influence the 
efficacy and safety of the pharmaceutical products. Impurity profiling (i.e., the 
identity as well as the quantity of impurity in the pharmaceuticals), is now gaining 
critical attention from regulatory authorities. The different pharmacopoeias, such as 
the British Pharmacopoeia (BP), United States Pharmacopeia (USP), and Indian 
Pharmacopoeia (IP) are slowly incorporating limits to allowable levels of impurities 
present in the API`s or formulation. The international conference on Harmonization of 
Technical Requirements for registration of Pharmaceuticals for Human Use (ICH) has 
also published guidelines for validation of methods for analyzing impurities in new 
drug substances, products, residual solvents and microbiological impurities [7,8,9,10] 
1.3. Forced Degradation study 
According to an ICH guidance document, a stability-indicating method is “a 
validated quantitative analytical procedure that can detect the changes with time in the 
pertinent properties of the drug substance and drug product. A stability-indicating 
method accurately measures the active ingredients, without interference from 
degradation products, process impurities, excipients, or other potential impurities”. 
The demonstration of specificity and the ability of the method to monitor a change in 
the chemical properties of the drug over time, a forced degradation (stress testing ) 
study to be done on the drug substance and drug product. Forced degradation on the 
drug substance and product will (in addition to establishing specificity) also provide 
the following information[11]: 
1) Determination of degradation pathways of of drug substances and drug 
products 
2) Discernment of degradation products in formulations that are related to drug 
substances versus those that are related to non-drug substances (eg,excipients) 
3) Structure elucidation of degradation products 
4) Determination of the intrinsic stability of a drug substance molecule in 
solution and sold state 
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5) Reveal the thermolytic, hydrolytic, oxidative, and photolytic degradation 
mechanism of the drug substance and drug product. 
Experimental design  
In designing forced degradation studies , it must be remembered that more 
stenuous conditions than those used for accelerated studies (25O C/60% RH or 40o 
C/75% RH) should be used. At a minimum , the following conditions should be 
investigated: (1) acid and base hydrolysis, (2) hydrolysis at various Ph, (3)thermal 
degradation, (4)photolysis, and (5) oxidation. For the drug substance and drug 
product. The initial experiments should be focused on determining the conditions that 
degrade the drug by approximately 10% (care should be taken to avoid under 
stressing or unduly over-stressing the drug substance or product, for this may lead to 
aberrant and non-representative results. A degradation level of approximately 10% of 
the drug substance should be optimal for method optimization). However, some 
scientists have found it practical to begin at extreme conditions (80oC or even higher, 
0.5N NaOH, 0.5N HCl, 3% H2O2) and testing at shorter (2, 5, 8, and 24 hrs, etc) 
multiple time points, thus allowing for a rough evaluation of rates of degradation.  
Forced degradation is only considered complete after the manufacturing 
process is finalized, formulation established, and test procedures developed and 
qualified. Temperatures potentially generate a variety of impurities that may differ 
from that of the photolysis or pH conditions. The degraded drug products provide 
information into the potential impurities of the drug that may be generated during 
stability testing. Forced degradation studies can also be used to quickly assess 
packaging material compatibility or sensitivities [11] 
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1.4. Thresholds for degradation products in new drug products  
Reporting thresholds 
Table-1 
> 1g 
 
0.1% 
> 1g 0.05% 
Identification thresholds 
Table-2 
Maximum daily dose Threshold 
< 1mg 1.0% or 5 µg TDI, whichever is lower 
1mg – 10 mg 0.5% or 20 µg TDI, whichever is lower 
> 10 mg – 2g 0.2% or 3mg TDI , whichever is lower 
> 2 g 0.15% 
Qualification thresholds 
Table-3 
 
1. Thresholds for degradation products are expressed either as a percentage of 
the drug substance or as total daily intake (TDI) of the degradation product. 
Lower thresholds can be appropriate if the degradation product is unusually 
toxic.  
2. Higher thresholds should be scientifically justified. [12,13] 
1.5. Importance of analytical method for impurity quantification 
Use of analytical method is almost importance all phase of synthetic research 
and related areas. The analytical activities related to the estimation of impurity 
profiles do not come to an end after the R&D phase of the introduction of a new 
Maximum daily dose Threshold 
<10mg 1.0% or 50 µg TDI, whichever is lower 
10mg – 100 mg 0.5% or 20µg TDI, whichever is lower 
>100mg -2g 0.2% or 3mg TDI, whichever is lower 
>2g 0.15% 
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drug. It is essential to ensure that no new impurities appear in the course of scaling 
up procedure and the quantity of the impurities in the bulk drug identified during the 
synthetic research phase remain below the specification limits. For this reason the 
analytical control of all steps of scaling up procedure is of key importance. More or 
less the same applies to the cooperation or drug analysts in the course of production 
of bulk drug in the routine scale. The identification, structural elucidation, 
quantification of impurities and degradation products are of prime importance in the 
course of all the phase of research and development and production of drug 
formulation. The pharmaceutical analyst should have a clear picture about impurity 
profile of bulk drug used for the development of the formulation in order to able to 
differentiate between synthesis related impurities and degradation products. In such a 
way stability indicating nature of method established. These studies indicate which 
of the impurities in the bulk drug are degradation products types. The increase of 
these is expected during the stability studies while the synthesis related impurities are 
likely to remain constant. A number of articles have stated guidelines and designed 
approaches for isolation and identification of process-related impurities and 
degradation products, using Mass spectrometry (MS), Nuclear Magnetic Resonance 
(NMR), High performance Liquid  Chromatography (HPLC), Fourier Transform 
Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS), and Tandem Mass 
Spectrometry for pharmaceutical substances. [14] 
1.6 Instruments used to analyze the impurities  
1. Ultra Violet Spectroscopy  
2. IR Spectroscopy  
3. NMR Spectroscopy 
4. Mass Spectrometry  
5. Gas Chromatography 
6. HPLC 
1.7. Chromatography 
Chromatography is the collective term for a set of laboratory techniques for the 
separation of mixtures. It involves passing a mixture dissolved in a “mobile phase” 
through a stationary phase, which separates the analyte to be measured from other 
molecules in the mixture based on differential partitioning between the mobile and 
stationary phases.  
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Chromatography may be preparative or analytical. The purpose of preparative 
chromatography is to separate the components of a mixture for further use (and is 
thus a form of purification). Analytical chromatography is done normally with 
smaller amounts of material and is for measuring the relative proportions of analytes 
in a mixture.  
1.7.1. High performance liquid chromatography 
High performance liquid chromatography is now one of the most powerful 
tools in analytical chemistry. It has the ability to separate, identify, and quantitative 
the compounds that are present in any sample that can be dissolved in a liquid. Today, 
compounds in trace concentrations as low as parts per trillion [ppt] may easily be 
identified. HPLC can be, and has been, applied to just about any sample, such as 
pharmaceuticals, food, nutraceuticals, cosmetics, environmental matrices, forensic 
samples, and industrial chemicals.  
1.7.2 Types of HPLC techniques 
 a) Normal phase chromatography 
 b) Reversed phase chromatography 
a) Normal – Phase HPLC 
 Normal phase uses a polar normal – phase HPLC (NP-HPLC), or adsorption 
chromatography, this method separates analytes based on adsorption to a stationary 
surface chemistry and by polarity NP-HPLC uses a polar stationary phase and a non-
polar, non-aqueous mobile phase, and works effectively for separating analytes 
readily soluble in non-polar solvents. The analyte associates with and is retained by 
the polar stationary phase. Adsorption strengths increase with increased analyte 
polarity, and the interaction between the polar analyte and the polar stationary phase 
(relative to the mobile phase) increases the elution time. 
 
b) Reversed – Phase HPLC 
Reversed phase mode has a non- polar stationary phase and polar mobile 
phase. With these stationary phases, retention time is longer for molecules which are 
more non-polar, while polar molecules elute more readily.To increase retention time 
by adding polar mobile phase, thereby making the affinity of the hydrophobic analyte 
for the hydrophobic stationary phase stronger relative to more hydrophilic mobile 
phase. Similarly, Decrease retention time by adding organic solvent to the eluent.  
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1.7.2.1. Instrumentation 
Fig-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of HPLC 
 
i) Solvent delivery system 
The mobile phase is pumped under pressure from one or several reservoirs and 
flows through the column at a constant rate. With micro particulate packing, there is a 
high pressure drop across a chromatography column. Eluting power of the mobile 
phase is determined by its overall polarity, the polarity of the stationary phase and the 
nature of the sample components. For normal phase separations eluting power 
increases with increasing polarity of the solvent but for reversed phase separations, 
eluting power decreases with increasing solvent polarity. Optimum separating 
conditions can be achieved by making use of mixture of two solvents. 
 
 
ii) Pump 
High pressure pumps are required to force the solvent through packed 
stationary phase beds. An ideal pump should generate pressure up to 6000 psi (400 
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                   Reservoirs                                                            
                                                                                                           flow splitter 
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bar) with a pulse-free output giving a flow rate from 10mL/min to less than 1µl/min. 
these types of pumps are available.  
They are  
 Reciprocating pumps  
 Displacement pumps 
 Pneumatic pumps 
iii)  Sample introduction system 
A sample introduction system is required to deliver the sample to the 
head of the HPLC column. 
 There are two types of injectors 
¾ Manual injectors 
¾ Auto samplers 
iv) Column 
In order to achieve high efficiency of separation, the column material (micro 
particles, 5-10 µm size) packed in such a way that highest numbers of theoretical 
plates are possible. Silica (SiO2X H2 O) is the most widely used substance for the 
manufacture of packing materials. It consists of a network of siloxane linkages (Si-
O-Si) in a rigid three dimensional structure containing inter connecting pores. The 
most popular material is octadecyl – silica), which contains C18 chains, but materials 
with C2, C6, C8 and C22 chains are also available. During manufacture, such materials 
may be reacted with a small mono functional silane (e.g.trimethyl chloro silene) to 
reduce further the number of silanol groups remaining on the surface (end-capping) 
v)  Detectors 
The detector for an HPLC is the component that emits a response due to the 
eluting sample compound and subsequently signals a peak on the chromatogram.  
Type of detectors 
¾ UV Detector 
¾ Refractive index Detector 
¾ Fluorometric detection  
¾ Atomic spectroscopic Techniques 
¾ Ampherometric Detection 
¾ Conductivity Detector  
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1.8. ANALYTICAL METHOD DEVELOPMENT 
 HPLC method development and validation is important for the analyzing of 
drugs in my formulation. Whatever method is used for quantitation or identification of 
drug the method should be a validated one. The method must be able to detect or 
quantitative the particular drug in presence of other components. 
 The most difficult problem usually is where to start, what type of column is 
worth trying with what kind of mobile phase. While there are a number of HPLC 
methods available to the development chemist, perhaps the most commonly applied 
method is reversed phase chromatography method. The water soluble drug is further 
differentiated as ionic or nonionic which can be separated by reverse phase. Similarly, 
the organic soluble drugs can be classed as polar and non polar and equally separated 
by reverse phase. In some cases the non polar API any have to be separated using 
adsorption or normal phase HPLC, in which mobile phase would be non polar organic 
solvent. Samples like proteins, peptides nucleic acids and synthetic polymers are 
analyzed by using some special columns or ion pair reagents (i.e. 0.1% TFA)[15]  
1.8.1 General conditions to initiate HPLC method development 
 Either isocratic or gradient mode may be used to determine the initial 
conditions of the separation, following the suggested experimental conditions given in 
the Table-4. 
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Selection of initial HPLC chromatographic conditions 
Table -4 
Chromatographic 
variables 
Neutral 
compounds 
Ionic – acidic 
compounds 
(carboxylic acids) 
Ionic – basic 
compound 
(amines) 
Column dimension 
(length, i.d) 
250x4.6 mm. 250x4.6 mm. 250x4.6 mm 
Packing material  C18 or C8  C18 or C8 C18 or C8 
Particle size 5µm 10µm or 5µm 10µm or 5 µm 
Mobile phase 
Solvents A and B 
Water – 
acetonitrile 
Buffer - acetonitrile Buffer – 
acetonitrile 
Ratio 50:50 20:80 20:80 
Buffer and pH No buffer 
required  
Phosphate 25Mm 
3.0& 7.5 
Phosphate 25Mm 
3.0& 7.5 
Peak modifier  Do not use 
initially  
1% v/v acetic acid 0.1% v/v 
triethylamine 
Flow rate  1.0 to 2.0 
ml/min 
1.0 to 2.0 ml/min 1.0 to 2.0 ml/min 
Temperature  Ambient Ambient Ambient 
Injection volume 10µl to 25 µl 10µl to 25 µl 10µl to 25 µl 
Sample 
concentration 
< 100 µg < 100 µg < 100 µg 
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Column & mobile phase selection shall be done as per the table given below  
Table -5 
Method /Description/Column When the method preferred 
Reverse – Phase HPLC 
Water / organic mobile phase For neutral and non ionized compounds 
that dissolve in water / organic mixtures. 
Column: C18, C8, Phenyl, cyano, and Trimethylsilyl (TMS) Columns. 
Normal Phase HPLC 
Mixture of organic solvents as mobile 
phase  
For samples that do not dissolve in water 
/ organic mixture. 
Column: Silica, Cyano and Amino columns 
 
1.8.2. Selection of mobile phase 
 The selection of the mobile phase mainly based on the solubility and polarity 
of the compound. Usually, in RP-HPLC method water and organic solvents are used 
as the mobile phase. In NP-HPLC method non polar solvents like Hexane and THF 
were used. If the sample contains ionic or ionizable compounds, then use of a 
buffered mobile phase to ensure the reproducible results. Under unfavorable 
circumstances, pH changes as little as 0.1 pH units can have a significant effect on the 
separation. On the other hand properly used buffer allows controlling the ph easily. 
Buffer works best at the pKa values of its acid. At this pH, the concentration of the 
acidic form and the basic form of the buffering species are equal, and the buffering 
capacity is maximum. Phosphate has three pKa values in the range of interest for 
silica based chromatography at pH 2, pH 7 and pH 12.32. The pKa of acidic buffer is 
4.75. Citrate has three pKa values 3.08, 4.77 and 6.40. Between citrate and phosphate 
buffers, the entire pH range useful for silica chromatography can be covered. In many 
cases, a silanophilic interaction causes tailin, mainly for the basic compounds due to 
ion-exchange interaction. This can usually be reduced or suppressed by the use of 
mobile phases modifies (0.1% v/v triethylamine for basic analyte or 1% v/v glacial 
acetic acid for the acidic analyte), or a combination thereof. Whenever buffers or 
other mobile phase activities are used, check the solubility in mobile phase. This is 
especially true for gradient applications. Acetonitrile is the preferred organic modifier 
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in reversed phase chromatograpy. Acetonitrile base mobile phases can give up to two 
fold lower pressure drop that can methanol based mobile phases at equal flow rate. 
This means that column efficiency is higher. The elution strength increases in the 
order methanol, acetonitrile and tetrahydrofuran. The retention changes by roughly 
1% for every 1% change in the concentration of organic modifier. 
<-----Non-polar-----Moderately polar----Polar-----> 
C18<C8<C6<Phenyl<Amino<Cyano<Silica. 
Experiments are to be conducted using different columns with different mobile phase 
to achieve best separation in chromatography. A column which gives separation of all 
the individual impurities and degradants from each other and from API peak and 
which is rugged for variation in mobile phase shall be selected.   
1.8.3 Selection of buffer 
 In reversed phase chromatography mobile phase pH values are usually 
between 2.0 and 7.5 buffers are needed when analyte is ionizable under reversed 
phase conditions or the sample solution is outside this pH range. Analyte ionisible 
under reverse phase conditions often have amine or acid functional group with pKa 
between 1.0 and 11.0. A form, whether ionic or neutral. If the sample solution is at pH 
damaging to the column, the buffer will quickly bring the pH of the injected solution 
to a less harmful pH. 
 If the analyte contain only amine functional group buffer selection is easier. 
Most amine will be in cationic form at pH values less than 9.0, so any buffer effective 
at pH 7.0 or lower will work. Buffer at pH 7.0 are used, even though pH of water is 
7.0, because amine retention and peak shapes are pH dependent. As pH is lowered 
amine retention time shortens and peak shape sharpens as the buffer protonates the 
acid silanols on silica surface. Any buffer with pKa less than 7.0 is suitable, but we 
have found potassium phosphate at pH 3.0 is best for amines. In both condition 
(acidic and alkaline) potassium phosphate buffer pH 3.0 works well in general is an 
excellent buffer for analyte that contains acidic and amine functional groups. The 
potassium salt works better than the sodium salt for amines. It is important to use the 
buffers with suitable strength to cope up for the injection load on the column 
otherwise peak tailing may arise during chromatography. Therefore, strength of the 
buffer should be suitable enough to take injection load on the column so that peak 
tailing is avoided. 
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 The retention time also depends on the molar strength is inversely proportional 
to the retention times. Ideally strength of the buffers shall be between 0.05M to 
0.20M. The selection of buffer and its strength is done always in combination with 
selection of organic phase composition in mobile phase. The strength of the buffer can 
be increased, if necessary, to achieve the required separation. But it is to be ensured 
that the higher buffer strengths shall not result in precipitants and turbidities either in 
mobile phase or in standard and test solution while allowed to stand in bench top or 
refrigerator. Experiments shall be conducted using different strengths to obtain the 
required separations.The buffers having a particular strength which gives separation 
of all individual impurities and degradation product. 
 
1.8.4. Selection of pH  
 pH is another factor in the resolution that will affect the selectively of the 
separation in reversed-phase HPLC. In reverse –phase chromatography sample 
retention(k`) increases when analyte is more hydrophobic (nonpolar).Sample retention 
(k`) decreases when the analyte is more hydrophilic (polar). Thus when an acid or 
base undergoes ionization it becomes more hydrophilic and less interacting with 
column binding sites. When the pH value of the value of the mobile phase equal to the 
pKa value of the analyte, it is said to be half ionized, i.e. the concentration of the 
ionized and unionized species are equal. As mostly all of the pH caused changes in 
the retention occur within ±2.0 pH unit of pKa value, it is the best to adjust the mobile 
phase to pH value at least ±2.0 pH unit above or below the pKa to ensure practically 
100% ionization of analyte for retention purpose. Generally at low pH peak tailing is 
minimized and method ruggedness is maximized. On the other hand, operating in the 
intermediate pH offers an advantage in increased analyte retention and selectivity. pH 
plays an important role in achieving the chromatographic separations as it controls the 
elution properties by controlling the ionization characteristics. Drug molecules 
retention time depending on the pKa value for example Acids shows an increase in 
retention as the pH is reduced, while base a show a decrease, experiments shall be 
conducted using buffers having different pH to obtain the required separations. It is 
importants to maintain the pH of the mobile phase in the range of 2.0 to 0.8 as most 
columns does not withstand to the pH which  are out of range. This is due to the fact 
that the siloxane linkages are cleaved below pH 2.0, while at values above 8.0 silica 
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may dissolve. If a pH outside the range of 2.0 to 8.0 is found to be necessary, packing 
materials which can withstand to that ranges shall be chosen. 
1.8.5 Selection of column 
 The HPLC column is the heart of the method. The column must posses the 
selectivity, efficiency and reproducibility to provide good separation. Commonly used 
reversed phase are cross linking Si-OH groups with alkyl chains like, C8 (octylsilane), 
C18 (octadecyl silane) and nitrile groups (CN), phenyl groups ( -C6H6) and amino 
groups (-NH2). They are chemically different phases and demonstrate significant 
changes in the selectivity using the same mobile phase. For example, a C8 phase 
(reverse phase) can provide a further time saving over a C18 as it doesn`t retain 
analyte as strongly as the C18 phase. 
The following are the parameters of a chromatographic column which are to be 
considered while choosing a column for separation of impurities and degradants. 
1. Length and diameter of the column  
 Column diameters employed in chromatography vary widely. In general, 
analytical columns have small diameter and preparative columns have wide 
diameters. Larger column (but in this case packed) having diameters between 0.5-2 
mm are employed for similar purpose in LC to produce very fast separations and high 
efficiencies. These LC column range in length from 10 cm to 2 m, the longer columns 
being rather difficult to pack. Packed columns having diameters ranging from 2 to 6 
mm ID are used in both GC and LC. 
2. Packing material 
 Porous silica particles are the most common substract material used for HPLC 
column packing. Silica-based columns can withstand high pressures, are compatible 
with most organic and aqueous mobile-phase solvents, and come in a wide range of 
bonded phases. Silica-based columns are often used for separations of low molecular 
weight analytes using mobile phase solvents and samples with a pH range of 2 to 7.5. 
Shape of the particles  
Irregular Shape 
 The first available HPLC columns were packed using irregularly shaped silica 
particles. Because of this, many standard analytical methods are still based on these 
materials. Irregular particles are also used in large-scale preparative applications 
because of their high surface area, capacity and low cost. 
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Spherical Shape 
 The majority of new HPLC methods are performed on spherical shaped or 
spheroidal(Almost spherical) particles. Sphericals particles provide higher efficiency, 
better column stability and lower back – pressures compared to irregularly shaped 
particles. 
3. Size of the particles 
 Particle size affects the back-pressure of the column and the separation 
efficiency. Column back-pressure and column efficiency are inversely proportional to 
square of the particles diameter. This means that as the particle size decreases, the 
column back – pressure and efficiency increase. Highly efficient, small-particle (3µm 
and 4 µm) columns are ideal for complex mixture with similar components. Fast high- 
resolution separations can be achieved with small particles packed in short(10-50 mm 
length) columns. 
4. Carbon loading. 
 The carbon load is measure of the amount of bonded phase bound to the 
surface of the packing. High carbon loads provide greater column capacities and 
resolution. Low carbon loads produce less retentive packings and faster analysis 
times. 
5. Pore volume. 
 Pore volume is a measurement of the empty space within a particle. Pore 
volume is a good indicator of the mechanical strength of a packing. Particles with 
large pore volumes are typically weaker than particles with small pore volumes. Pore 
volumes of 1.0 mL/g or less are recommended for most HPLC separations. Pore 
volumes of greater than 1.0mL/g are preferred for size-exclusion chromatography and 
useful for low-pressure methods. 
6. Surface area 
 The physical structure of the particle substrate determines the surface area of 
the packing material. Surface area is determined by pore size. Pore size and surface 
area are inversely related. A packing material with a small pore size will have a large 
surface area, and vice versa. High surface area materials offer greater capacity and 
longer analyte retention times. Low surface area packings offer faster equilibration 
time and are often used for large molecular weight molecules. 
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7. End capping. 
 A reversed-phase HPLC column that is end-capped has gone through a 
secondary bonding step to cover unreacted silanols on the silica surface. End-capped 
packing materials eliminate unpredictable secondary interactions. Basic produce 
asymmetric tailed peaks on non end-capped columns, requiring the addition of 
modifiers to the mobile phase. Non end capped materials exhibit different selectivity 
than end-capped. 
8. Column dead volume 
 An accurate estimation of the dead volume is very important when measuring 
retention data, particularly if the corrected retention volume is small and 
commensurate with dead volume. The dead volume comprises a number of different 
components a number of different components of the column volume, and the 
distribution of the total column volume into those parts of chromatographic 
significance is a little complicated. [16]  
1.8.6. Selection of Column temperature 
Temperature variation over the course of a day has quite significant effect on 
HPLC separations. This can even occur in air conditioned rooms. While temperature 
is a variable that can affect the selectivity, its effect is relatively small. Always it is 
preferable to optimize the chromatographic conditions with column temperature as 
ambient. However, if the peak is symmetry could not be achieved by any combination 
of column and mobile phase, then the column temperatures above ambient can be 
adopted. The increase in column temperature generally will result in reduction in peak 
asymmetry and peak retentions. When found necessary, the column temperatures 
between 30oC and 80oC shall be adopted. If a column temperature of above 80oC is 
found to be necessary, packing materials which can withstand to that temperature 
shall be chosen. 
1.8.7 Selection of flow rate  
Flow rate, more for isocratic than gradient separation, can sometimes be useful 
and readily utilized to increase the resolution, although its effect is very modest. The 
slower flow rate will also decrease the column back pressure.  
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Flow rate shall be selected based on the following data. 
1. Retention times 
2. Column back pressures 
3. Separation of impurities (resolution) 
4. Peak symmetries 
Preferably the flow rate shall be not more than 2.5 ml/min. Check the 
ruggedness of the method by varying the flow rate by = 0.2 ml from the selected flow 
rate. Select the flow rate which gives least retention tomes, good peak symmetries, 
least back pressures and better separation of impurities from each other and from API 
peak. 
1.8.8. Selection of solvent delivery system 
Chromatographic separation with a single eluent (isocratic elution) i.e.: All the 
constituents of the mobile phase is mixed and pumped together as single eluent is 
always preferable. Gradient elution is a powerful tool in achieving separation between 
closely eluting compounds or compounds having widely differing in polarities.The 
important feature of the gradient elution which makes it a powerful tool is that the 
polarity and ionic strength of the mobile phase can be changed (can be increased or 
decreased) during the run. Conduct experiments using different mobile phase 
combinations and different gradient programme to achieve separation of all the 
impurities and degradants from other and from API peak. In general, while running a 
gradient, two mobile phases having different composition is kept in different 
channels.  
1.8.9. Selection of detector wavelength 
 Selection of detector wavelength is a critical step in finalization of the 
analytical method for impurities and degradants. Inject the impurity and API standard 
solutions into the chromatographic system with photodiode array detector and collect 
the spectra. Also conduct forced degradation studies and collect the UV spectra of all 
the major degradation products. Overlay the spectra of all the compounds and select a 
wavelength which is most common and gives higher responses for all compounds.  
1.8.11. Selection of test concentration, injection volume 
 The test concentration is generally chosen based upon the response of API 
peak and impurities at the selected detector wavelength. The test concentration shall 
be finalized after it is proved that API is completely extractable at the selected test 
concentration. Generally an injection volume of 10 to 20µl is recommended for 
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estimation of impurities. If the extractions are found to be difficult, then the test 
concentrations can be kept low and the injection volume can be increase up to 50µl. 
But it is to be ensured that at the selected injection volume the column is not 
overloaded, resolution between individual impurities and the peak symmetries are not 
compromised. After the test concentration and the diluents is finalized, prepare a test 
solution and keep the filtered solution in closed condition in a stoppered flask on the 
bench top and observe for any precipitation or turbidity after 24 hours. The solution 
should not show any turbidity / precipitation [17,18] 
1.9. Analytical Method Validation 
Validation definition  
 Validation is establishing documented evidence which provides a high degree 
of assurance that a specific process will consistently produce a product meeting its 
predetermined specifications and quality attributes. 
 
 
 Typical validation characteristics which should be considered are listed below. 
¾ Accuracy  
¾ Precision 
¾ Repeatability 
¾ Intermediate precision 
¾ Specificity  
¾ Detection Limit 
¾ Quantitation Limit 
¾ Linearity  
¾ Range 
¾ Robustness 
¾ Ruggedness 
Furthermore revalidation may be necessary in the following circumstances 
¾ Changes in the synthesis of the drug substance 
¾ Changes in the composition of the finished product 
¾ Changes in the analytical procedure 
The degree of revalidation required depends on the nature of the changes. Certain 
other changes may require validation as well[13]. 
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1.9.1. Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically these might include 
impurities, degradants, matrix, etc. lack of specificity of an individual analytical 
procedure may be compensated by other supporting analytical procedure(s). 
1.9.2 Accuracy 
The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. This is sometimes termed trueness. 
Accuracy studies for drug substance and drug product are recommended to be 
performed at the 80, 100 and 120%levels of label claim as stated.  
For the drug product, this is performed frequently by the addition of known 
amounts of drug by weight or volume to the placebo formulation working in the linear 
range of detection of the analyte 
It is calculated as the percentage of recovery by the assay of the known added 
amount of analyte in the sample or as the difference between the mean and the 
accepted true value together with confidence intervals. It should be assessed using a 
minimum of three concentrations and three replicates of each concentration. 
Acceptance criteria: based on statistical significance of the test of the null 
hypothesis that the slope is 1.0 is not an acceptable approach. 
1.9.3. Precision 
The precision of an analytical procedure is the degree of agreement among 
individual test results when the procedure is applied repeatedly to multiple samplings 
of a homogeneous sample. It is usually expressed as the standard deviation or relative 
standard deviation (coefficient of variation) of series of measurements. It can be sub 
divided into three categories.  
A) Repeatability 
 B) Intermediate precision 
C) Reproducibility 
A) Repeatability  
a) Injection Repeatability  
It is measured by multiple injections of a homogeneous sample indicates the 
performance of the HPLC instrument under the chromatographic conditions and day 
tested.  
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Recommendations 
i) As part of methods validation, a minimum of 10 injections with an RSD of < 1 
% is recommended.  
 
b)  Analysis repeatability 
It consists of multiple measurements of a sample by the same analyst under 
the same analytical conditions. For practical purpose, it is often combined with 
accuracy and carried out as a single study.  
B) Intermediate precision (part of ruggedness) 
The long – term variability of the measurement process and is determined by 
comparing the results of a method run within a single laboratory over a number of 
weeks. A method` intermediate precision may reflect discrepancies in results obtained 
by different operators, from different instruments, with standards and reagents from 
different suppliers, with columns from different batches or a combination of these. 
The objective of validation is to verify that in the same laboratory the method will 
provide the same results once the development phase is over.  
C) Reproducibility 
The reproducibility of an analytical method is determined by analyzing 
aliquots from homogeneous lots in different laboratories with different analysts and 
by using operational and environmental conditions that may differ from but are still 
within the specified parameters of the method. 
a) Typical variations affecting a method`s reproducibility  
b) Differences in room temperature and humidity 
c) Operators with different experience and thoroughness 
d) Equipment with different characteristics 
e) Variations in material and instrument conditions 
f) Equipment and consumables of different ages 
g) Columns from different suppliers or different batches 
h) Solvents, reagents and other materials with different quality. 
Acceptance criteria 
1) % RSD should be less than 10.0% (For residual solvents) 
2) % RSD should be less than 1.0% (For Assay) 
3) %RSD should be less than 5.0% (For related substances) 
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1.9.4. Detection limit 
 The detection limit of an individual analytical procedure is the lowest amount 
of analyte in a sample which can be detected but not necessarily quantitated as an 
exact value.  
LOD = 3.3 σ /S 
 Where σ is the standard deviation of the response and S is the slop of the 
calibration curve (of the analyte). 
1.9.6 Linearity 
 The linearity of an analytical procedure is ability to obtain test results which 
are directly proportional to the concentration of analyte in the sample. The goal is to 
have a model, whether linear or nonlinear, that describes closely the concentration-
response relationship. 
 Linearity should be established across the range of the analytical procedure. 
The correlation coefficient, y-intercept, slope of the regression line, and residual sum 
of squares should be submitted. 
 For the linearity study, a minimum of five concentrations normally be used. 
The following minimum specified ranges should be considered. 
a) Assay of a drug substance (finished product): from 80% to 120% of the test 
concentration.  
b) Determination of an impurity: from 50% to 120% of the acceptance criterion. 
c) For content uniformity: a minimum of 70% to 130% of the test concentration, 
unless a wider or more appropriate range based on the nature of the dosage 
form. 
1.9.7. Range 
 The range of suitability of a given analytical procedure is the interval between 
minimum and maximum concentrations of compound to be determined in which. 
1) The linearity is observed 
2) The characteristics of repeatability fall within permissible limits 
3) The accuracy is maintained at a sufficiently high level. 
This range could be determined using threshold RSD values obtained in the 
course of validation of the linearity and precision.  
1.9.8. Robustness 
 The concept of robustness of an analytical procedure has been defined by the 
ICH as “a measure of its capacity to remain unaffected by small, but deliberate 
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variations in method parameters”. The most important aspect of robustness is to 
develop methods that allow for expected variations in the separation parameters.  
1) The content of the organic solvent in the eluent (+2%) 
2) The amount of additives (salts, ion-pair reagents etc) in the eluent (+10%) 
3) pH of the buffer solution (+0.5) 
4) HPLC column temperature (+5₀c) 
5) Time of extraction of the analyzed compound from a drug eluent (+20%) 
6) Extractant composition (+5%) 
7) Eluent concentration gradient (+2%) 
8) Mobile phase flow rate 
9) Column type and / or manufacturer 
1.9.9. Ruggedness 
The long – term variability of the measurement process and is determined by 
comparing the results of a method run within a single laboratory over a number of 
weeks. A method`s intermediate precision may reflect discrepancies in results 
obtained by different operators, from different instruments, with standards and 
reagents from different suppliers, with columns from different batches or a 
combination of these. The objective of validation is to verify that in the same 
laboratory the method will provide the same results once the development phase is 
over.[19,20,21]  
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Acute Mountain Sickness: Dosage is 250 mg to 500 mg daily, in divided 
doses using tablets or extended release capsules as appropriate. In circumstances of 
rapid ascent, such as in rescue or military operations, the higher dose level of 500 mg 
is recommended. It is preferable to initiate dosing 24 to 48 hours before ascent and to 
continue for 48 hours while at high altitude, or longer as necessary to control 
symptoms.  
NDC 51285 – 754 – 02 
Store at controlled room temperature 20 o to 25 o C (68 o to 77o F) 
SIDE EFFECTS 
Body as whole:  headache, malaise, fatigue, fever, pain at injection 
site, flushing, growth retardation children ,flaccid 
paralysis, anaphylaxis. 
Digestive:  gastrointestinal disturbances such as nausea, 
vomiting, diarrhea 
Hematological / 
Lymphatic: Blood dyscraias such as aplastic anemia, 
agranulocytosis, leucopenia, throm bocytopenic 
purpura, melena 
Hepato-biliary disorders:  abnormal liver function, cholestatic jaundice, 
hepatic insufficiency, fulminant hepatic necrosis 
Metabolic/nutritional:  metabolic acidosis, electrolyte imbalance, including 
hypokalemia, hyponatremia, osteomalacia with long 
– term phenytoin therapy, loss of appetite, taste 
alteration, hyper/hypoglycemia 
Nervous:  Drowsiness, peresthsia (including numbness and 
tingling of extremities and face), depression, 
excitement, ataxia, confusion, convulsions 
dizziness. 
Skin:  Allergic skin reactions including urticaria, 
photosensitivity, stevens-johnson syndrome, toxic 
epidermal necrolysis 
Special senses:  hearing disturbances, tinnitus, transient myopia 
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Urogenital: crystalluria, increased risk of nephrolithiasis with 
long term therapy, hematuria, glycosuria, renal 
failure polyuria. 
DRUG INTERACTIONS 
Acetazolamide extended release capsules modifies phenytoin metabolism with 
increased serum levels of phenytoin. This may increase or enhance the occurrence of 
osteomalacia in some patients receiving chronic phenytoin therapy. Caution is advised 
in patients receiving chronic concomitant therapy. By decreasing the gastrointestinal 
absorption of primidone, Acetazolamide extended release capsules may decrease 
serum concentrations of primidone and its metabolites,with a consequent possible 
decrease in anticonvulsant effect, caution is advised when beginning , discontinuing , 
or changing the dose of Acetazolamide extended release capsules in patients receiving 
primidone. 
Because of possible additive effects with other carbonic anhydrase inhibitors, 
concomitant use is not advisable. 
Acetazolamide may increase the effects of other folic acid antagonists. 
Acetazolamide decreases urinary excretion of amphetamine and may enhance 
the magnitude and duration of their effect. 
Acetazolamide reduces urinary excretion of quinidine and may enhance its 
effect. Acetazolamide may prevent the urinary antiseptic effect of methenamine 
acetazolamide increases lithium excretion and the lithium may be decreased.  
Acetazolamide and sodium bicarbonate used concurrently increases the risk of 
renal calculus formation.  
Acetazolamide may elevate cyclosporine levels. 
PRECAUTIONS 
General  
Increasing the dose not increase the dieresis and may increase the incidence of 
drowsiness and /or pareshesia. Increasing the dose often results in a decrease in 
dieresis. Under certain circumstances, however, very large doses have been given in 
conjunction with other diuretics in order to secure dieresis in complete refractory 
failure.  
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Laboratory Tests 
To monitor for hematologic reactions common to all sulfonamides, it is 
recommended that a baseline CBC and platelet count be obtained on patients prior to 
initiating therapy and at regular intervals during therapy. If significant changes occur, 
early discontinuance and institution of appropriate therapy are important. Periodic 
monitoring of serum electrolytes is recommended. 
Carcinogenesis, mutagenesis, impairment of fertility 
Long –term studies in animals to evaluate the carcinogenic potential of 
Acetazolamide extended release capsules have not been conducted in a bacterial 
mutagenicity assay, Acetazolamide extended release capsules was not mutagenic 
when evaluated with and without metabolic activation. 
The drug had no effect on fertility when administered in the diet to male an 
female rats at a daily intake of up to 4 times the recommended human dose of 1000 
mg in a 50 kg individual  
Pregnancy: Teratogenic effects: Pregnancy Category C 
Acetazolamide, administered orally or ally or parenterally, has been shown to 
be teratogenic (defects of the limbs) in mice, rats, hamsters, and rabbits. There are no 
adequate and well controlled studies in pregnant women. Acetazolamide should be 
used in pregnancy only if the potential benefit justifies the potential risk to the fetus.  
Nursing mothers 
Because of the potential for serious adverse reactions in nursing infants from 
Acetazolamide extended release capsules a decision should be made whether to 
discontinue the drug taking into account the importance of the drug to the mother. 
Acetazolamide should only be used by nursing women if the potential benefit justifies 
the potential to the child 
Pediatric Use 
The safety and effectiveness of Acetazolamide extended release capsules in 
pediatric patients below the age of 12 years have not been established. Growth 
retardation has been reported in children receiving long term therapy, believed 
secondary to chronic acidosis. 
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Geriatric Use 
Metabolic acidosis, which can be severe, may occur in the elderly with 
reduced renal function.  
In general, dose selection for an elderly patent should be cautious, usually 
starting at the low end of the dosing range, reflecting the greater frequency of 
decreased hepatic, renal or cardiac function, and concomitant disease or other drug 
therapy. 
Overdose 
No specific antidote is known. Treatment should be symptomatic and 
supportive. 
Electrolyte imbalance, development of an acidotic state, and central nervous 
system effects might be expected to occur, serum electrolyte levels (particularly 
potassium) and blood pH levels should be monitored. 
Supportive measures are required to restore electrolyte and pH balance. The 
acidotic state can usually be corrected by the administration of bicarbonate. 
Despite its high intraerythrocytic distribution and plasma protein binding 
properties.   Acetazolamide extended release capsules may be dialyzable. This may be 
particularly important in the management of Acetazolamide extended release capsules 
overdosage when complicated by the presence of renal failure 
Contraindications 
Hypersensitivity to acetazolamide or any excipients in the formulation. Since 
acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, 
sulfonamides and other sulfonamide derivatives is possible.  
Acetazolamide therapy is contraindicated in situations in which sodium and / 
or potassium blood serum levels are depressed, in cases of marked kidney and liver 
disease or dysfunction, in suprarenal gland faiure, and in hyperchloremic acidosis. It 
is contraindicated in patients with cirrhosis because of the risk of development of 
hepatic encephalopathy.  
Long term administration of Acetazolamide extended release capsules IS 
contraindicated in patients with chronic non congestive angle closure glaucoma since 
it may permit organic closure of the angle to occur while the worsening glaucoma is 
masked by lowered intraocular pressure.  
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Uses: 
Acetazolamide is used to prevent and reduce the symptoms of altitude 
sickness. This medication can decrease headache, tiredness, nausea, dizziness, and 
shortness of breath that can occur when your climb quckly to high altitude (generally 
above 10,000 feet/3,048 meters) it is particularly useful in situations when you cannot 
make a slow ascent. The best ways to prevent altitude sickness are climbing slowly, 
stopping for 24 hours during the climb to allow the body to adjust to the new height, 
and taking it easy the first 1 to 2 days. 
This drug is also used with other medications to treat a certain type of eye 
problem (open – angle glaucoma). Acetazolamide is a “water pill” (diuretic). It 
decreases the amont of fluid that can build up in the eye. It is also used to decrease a 
buildup of body fluids (edema) caused by congestive heart failure or certain 
medications. Acetazolamide can work less well over time, so it is usually used only 
for a short period.  
It has also been used with other medications to treat certain types of seizures.  
Side effects 
Dizziness, lightheadedness and an increased amount of urine may occur , 
Blurred vision, dry mouth , drowsiness, loss of appetite, stomach upset, headache , 
tiredness and allergic reaction.  
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3. LITERATURE REVIEW 
B.Ihssane, et al., This paper describes the optimization and validation of an 
analytical method for HPLC analysis of acetazolamide in tablets using BoxBehnken 
design. This multivariate approach enables substantial improvement of 
chromatographic performance using fewer experiments, without additional cost of 
columns orth equipment. By use of quadratic regression analysis, equations were 
developed describing the behavior of the response as simultaneous functions of the 
selection independent variables. Accordingly, the optimum conditions were 
determined. Further quality control samples there were use of a C18 column with 
acetonitrile phosphoric acid buffer solution (0.01M, pH 7.1)15:85 (v/v) as mobile 
phase at a flow rate 0.1 mL min-1 Diode-arrey detection was performed at 266nm. The 
method was validated, in accordance with ICH guidelines, for accuracy, precision 
selectivity, and linearity. The method is simple, rapid, sensitive and accurate and the 
retention time is less than 4min. the method is therefore suitable for routine quality-
control monitoring of acetazolamide in tablets[25]. 
B.Ramesh et al., A new quantitative densitometric High performance Thin 
Layer Chromatographic the analysis and stability indicating determination of 
acetazolamide, both in bulk and formulations. Acetazolamide from the formulations 
gel 60 F254 HPTLC plates with toluene: acetone: methanol (6:2:2 v/v), as mobile 
phase. Densitometric quantification was performed at I= 270 nm by refle resolved 
band for the main drug (Rf 0.53±0.02). Linear regression concentration analysis data 
for mean calibration plots showed good linear relationship in the coefficient, slope 
and intercept of 0.9991±0.00047, 11.28±0.351 and 131.32±1.52 respectively.The 
minimum amount of acetazolamide that could be authentically 40.23 ng/spot, 
respectively. The drug was subjected to acid, base, neutral hydrolysis, oxidation, 
photolysis and thermal decomposition to establish a validate drug undergoes 
degradation under acid, base, neutral and oxidative stress conditions. Also the 
degraded products were well separated from pure drug with proposed method was 
validated with respect to linearty, precision, accuracy, specificity and robustness. 
Further, the proposed HPTLC method was employed to and observed that the 
degradation process followed pseudo first order kinetics. Thus, the Arrhenius plot was 
constructed and activation energy was calculated[26]. 
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Dennis J. Capron et al., A high – performance liquid chromatographic 
method for the determination of acetazolamid concentrations of acetazolamide were 
spiked with the internal standard, Sulfadiazine.Sam 25 s in boiling water. All samples 
were extracted with ethyl acetate; a phosphate buffer which was then washed with 
ether. Separation of acetazolamide and internal standard from acetonitrile- methanol- 
acetate buffer (pH 4.0). The eluant was monitored at 254 nm. All ca the method to 
human pharmacokinetic studies was demonstrated[27]. 
 
Shalini pachauria et al., A simple, precise, fast and gradient, high 
performance liquid chromatographic (HPLC) method was developed and validated for 
the determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in solid 
dosage forms. The quantitative determination of analyte(s) was performed on a 
PUROSPHERE STAR rp 18e analytical column (250x4.6 mm) with 0.2 % v/v TEA 
buffer (pH: 3.0): CAN as mobile phase, at a flow rate of 1.0 ml min- 1. Detection was 
made by extracting PDA spectra at 215 nm respectively. During method validation, 
parameters such as precision, linearity, stability, Robustness, Ruggedness and 
specificity were evaluated, which remained within acceptable limits. The method has 
been successfully applied to assess the assay of solid dosage formulations[28].  
M.I. Walash et al., A simple and sensitive spectrophotometric method was 
developed for the determination of acetazolamide (ACM) in pure form and 
pharmaceutical preparations. The proposed method is based on the complex formation 
of acetazolamide with Palladium (II) chloride in acetate buffer pH 5.4 and measuring 
the absorbance at 308 nm. The absorbance- concentration plot was rectilinear over the 
concentration range of 5-70 μg/ml with a minimum detection limit (LOD) of 0.98 
μg/ml, limit of quantification (LOQ) of 2.96 μg/ml, and a molar absorptivity ζ = 2.7 × 
103 L/mol.cm. The factors affecting the absorbance of the formed complex were 
carefully studied and optimized. The composition of the complex as well as its 
stability constant was also investigated. The proposed method was applied for the 
determination of acetazolamide in its tablets and the results obtained were favorably 
compared with those obtained using the official method. A proposal of the reaction 
pathway was postulated[29]. 
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     Morra V et al., An analytical procedure was developed for the fast 
screening of 16 diuretics (acetazolamide, althiazide, amiloride, bendroflumethiazide, 
bumetanide, canrenoic acid, chlorthalidone, chlorthiazide, clopamide, ethacrynic acid, 
furosemide, hydro chlorthiazide, hydroflumethiazide, indapamide, triamterene, 
trichlormethiazide) and a masking agent (probenecid) in human urine. The whole 
method involves three analytical steps, including (1) liquid/liquid extraction of the 
analytes from the matrix, (2) their reaction with methyl iodide at 70 degrees C for 2 h 
to form methyl derivatives, (3) analysis of the resulting mixture by fast gas 
chromatography/electron impact mass spectrometry (fast GC/EI-MS). The analytical 
method was validated by determining selectivity, linearity, accuracy, intra and inter 
assay precision, extraction efficiencies and signal to noise ratio (S/N) at the lowest 
calibration level (LCL) for all candidate analytes. The analytical performances of 
three extraction procedures and five combination of derivatization parameters were 
compared in order to probe the conditions for speeding up the sample preparation 
step. Limits of detection (LOD) were evaluated in both EI-MS and ECNI-MS 
(electron capture negative ionization mass spectrometry) modes, indicating better 
sensitivity for most of the analytes using the latter ionization technique. The use of 
short columns and high carrier gas velocity in fast GC/MS produced efficient 
separation of the analytes in less than 4 min, resulting in a drastic reduction of the 
analysis time, while a resolution comparable to that obtained from classic GC 
conditions is maintained. Fast quadrupole MS electronics allows high scan rates and 
effective data acquisition both in scan and selected ion monitoring modes[30]. 
 
Philip T. A simple, rapid and specific HPLC method has been developed to 
determine acetazolamideconcentrations in human plasma. The assay procedure 
requires only 250 μl of sample with direct injection of the organic supernatant after 
protein precipitation with acetonitrile. Chlorothiazide was used as an internal 
standard. A reversed-phase C18 μBondapak column was employed for the 
chromatographic separation. The eluent was monitored at 265 nm using a UV variable 
wavelength detector. The retention times for acetazolamide (ACZ) and chlorothiazide 
(CTZ) were 6 and 8 min respectively. A linear relationship (r).995) was obtained over 
the 1-20 μg/ml concentration range. The limit of sensitivity for ACZ was 0.5 
μg/ml,with greater than 85% recovery of ACZ and internal standard. The method was 
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applied to human plasma samples obtained after administration of a 250 mg 
acetazolamide tablet[31]. 
V. Das Gupta Stability-indicating reverse phase high-pressure liquid 
chromatography methods to quantify acetazolamide in pharmaceutical dosage forms 
have been developed. The methods are accurate and precise with percent relative 
standard deviations based on six injections of 0.9 with a semipolar column and 0.4 
with a nonpolar column. No preliminary extraction procedure is required to assay the 
acetazolamide sodium in vials and a very simple extraction is needed to extract 
acetazolamide from the tablets or contents of the capsules. Acetazolamide appears to 
be very unstable in the presence of 0.1N NaOH with a half-life of about 14 days. It 
underwent hydrolysis to acetic acid and 5-amino-1, 3, 4-thiadiazole-2 sulfonamide. 
The hydrolysis followed first-order law with a K value of 0.0495 day-1 at 25°[32]. 
W. F. Bayne* A method for the analysis of acetazolamide, 5-acetamido-1,3,4-
thiadiazole-2-sulfonamide, sensitive to 25 ng/ml in plasma, was developed. After 
extraction of acetazolamide and its propionyl analog, 5-propionamido-1,3,4-
thiadiazole-2-sulfonamide, the internal standard, from plasma with ethyl acetate and 
removal of lipids from the residue of the ethyl acetate extract with methylene 
chloride, the sulfonamides were chromatographed on an octadecyl trichlorosilane 
bonded phase using high-pressure liquid chromatography. The method was developed 
to study plasma level profiles of different dosage forms of acetazolamide[33]. 
Gomaa ZS . A high performance liquid chromatographic assay for the 
quantitation of acetazolamide in both tablet and injection form is described. 
Acetazolamideis extracted with 0.005 M NaOH solution containing 0.3 mg/mL 
sulphadiazine (internal standard). A commercially available mu-Bondapak C18 
cartridge column was used for the separation together with a mobile phase made of 
acetonitrile, methanol and sodium acetate buffer mixture (10:2:88) (pH 4) at a flow- 
rate of 4 mL/min. Retention times of about 2.50 and 3.36 min were obtained for the 
drug and the internal standard, respectively[34]. 
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4. AIM AND OBJECTIVE 
 
Acetazolamide is a carbonic anhydrase inhibitor, mainly used to reduce intraocular 
pressure in the treatment of long term management of glaucoma 
A few chromatographic method have appeared in the literature for the quantification 
of Acetazolamide in human and rat plasma. Several other method have been 
published for quantification of Acetazolamide in human urine  
The aim of the current study was to develop a validated, specific and stability 
indicating reverse phase liquid chromatographic method for the quantitative 
determination of Acetazolamide and its related substances.  
This study is designed to develop a novel method for the estimation of Acetazolamide 
SR capsules and its related substance like impurity –D (process related degradation 
impurity) and impurity–E (Forced Degradation impurity). 
 
Objective  
1. To develop a novel stability indicating method for the estimation of 
Acetazolamide and its related substance.  
2. To validate the developed method for the estimation of selected drug and its 
related substances in sustained release formulation as per ICH guidelines  
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6. MATERIALS AND METHODS 
MATERIALS 
1. Chromatographic system 
Instrument  : High Performance Liquid Chromatography            
system(HPLC) 
Instrument ID  : QHPL 4012, QHPL 4013,QHPL4009 
Make   : Waters  
2. Anaylytical balance (2mg-200g) 
Instrument ID  : IEWS4034,IEWS4038, IEWS4037 
Make   : Satorius 
3. Acetazolamide Standard  
Batch No  : AWS –A03-00 
Potency   : 99.7% 
4. Reagents 
Potassium dihydrogen orthophosphate: Merck 
Acetoniltrile   : HPLC Grade 
Water   : Milli-Q 
5. Column 
Synergi polar RP Phenomenex C-18 (150x4.6mm,4.0µm 
6. Mobile phase 
Acetonitrile : Buffer   (100:900) 
METHOD DEVELOPMENT AND VALIDATION 
Selection of Solvent: 
Acetazolamide is readily soluble in potassium dihydrogen orthophosphate 
buffer. So mobile phase was used as a solvent of choice for the drug. 
Optimization of mobile phase: 
After many trials being done on the basis of pKa, solubility study results of the 
drug and review of literature survey potassium dihydrogen ortho phosphate and was 
choosen for buffer preparation. (fig-3.1 to fig-3.8) 
Selection of column: 
Experiments with deferent C-18 columns were conducted to achieve best 
separation of analyte peak with other blank and placebo peaks. C18 columns such as 
waters x-terra C-18 , inertsil C-18 , waters symmetry C-18, Hypersil BDS C-18, 
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Hypresil ODS C-18, Synergi polar RP phenomenex C-18 e.t.c were tried. (fig-2.1 to 
fig-2.7)  
Detection and selection of wavelength: 
Known concentration of Acetazolamide working standard was taken and 
dissolved in mobile phase such that the standard solution contains about 0.8ppm. 
placebo and blank solutions also prepared. All these solution were scanned between 
200-400 nm using UV Visible Spectrophotometer then these are subjected to 
chromatograph containing PDA detector to determine accurate and optimized 
wavelength. After reviewing chromatograms and peak purity, a wavelength of 265nm 
is selected as the wavelength for this drug.  
Selection of Flow Rate 
Select the flow rate which gives least retention time, good peak symmetries , 
least back pressures and better separation of impurities from each other and from API 
peak.  
 After reviewing the result it was found that the flow rate having a 
1.0ml /min. which have given least retention time , good peak symmetry , and better 
separation of impurities from each other and from API peak. (fig-4.1 to fig-4.3) 
Preparation of buffer solution: 
Weigh accurately and dissolve about 6.8g of potassium dihydrogen 
orthophosphate in 1000 mL of water and mix well. Filter through 0.45 µm nylon 
membrane filter and degas. pH of the buffer solution is 4.5. 
Preparation of mobile phase: 
Prepare a mixture of 900 mL of buffer solution and 100 mL of acetoniltrile 
and degas.  
Preparation of diluent: 
Mobile phase is used as diluents.  
Impurity Stock Solutions:  
Weigh accurately and transfer about 2 mg of impurity –E, 2mg of impurity –D 
, into a 25 mL volumetric flask. Add about 15 mL of methanol and sonicate to 
dissolve. Make the volume up to the mark with methanol and mix.  
Preparation of standard solution: 
Weigh accurately and transfer about 40.0 mg of Acetazolamide working 
standard in to a 100mL volumetric flask. Add About 60mL mobile phase and sonicate 
to dissolve. Dilute to volume with mobile phase and mix. Transfer 1mL of this 
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solution in to a 100mL volumetric flask and make the volume up to the mark with 
mobile phase. Further dilute 2mL of this solution in to 10mL with mobile phase and 
mix. (conc.0.8 PPM) 
 
Preparation of sample solution  
Weigh not less than 20 capsules and empty the contents and weigh the empty 
capsules. Calculate the average fill weight. Weigh accurately pellets equivalent to 40 
mg of Acetazolamide and transfer in to a 100 mL volumetric flask. Add about 60mL 
of mobile phase and sonicate for 15 minutes with intermittent shaking. Cool the 
solution to room temperature and make the volume up to the mark with mobile phase 
and mix (conc:0.4mg/mL). Filter through 0.45 µ nylon syringe filter.  
Note: 
1. Prepare sample solution in duplicate 
2. Filtered sample solution stable for 48 hours at ambient condition 
Placebo preparation: 
Weigh accurately and transfer of each strength equivalent to 40mg of 
Acetazolamide (substract the 40mg from the obtained equivalent weight) into a 
100mL volumetric flask. Add about 60mL of mobile phase and sonicate for 
15minutes with intermittent shaking. Cool the solution to room temperature and make 
up the volume up to the mark with mobile phase and mix (conc:0.4mg /mL). Filter 
through 0.45 µ nylon syringe filter. 
Preparation of impurity spiked sample solution 
Weigh not less than 20 capsules and empty the contents and weigh the empty 
capsules. Calculate the average fill weight. Weigh accurately pellets equivalent to 
40mg of Acetazolamide and transfer into a 100mL volumetric flask. From the above 
impurity stock solution pipette out 0.75 mL into the volumetric flask add about 60mL 
of mobile phase and sonicate for 15min with intermediate shaking. Cool the solution 
to room temperature and make up the volume upto the mark with mobile phase and 
mix. 
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Evaluation of system suitability  
1. Resolution between impurity –E and Impurity-D in resolution solution 
should not be less than 2.0 
2. The % RSD of the areas of Acetazolamide peak obtained from the 
chromatograms of six replicate injection s of standard solution should not 
be more than 5.0 
Note 
The retention time for Acetazolamide peak is about 7.5 minutes.  
 
RRT and RRF table: 
Table -7 
S.No Name of Impurity RRT RRF 
1 Impurity –D 0.40 0.64 
2 Impurity –E 0.34 - 
 
CALCULATION : 
 
Calculate the % content of impurity D by the below formula 
ATI     WS       1        2 100       Avg.Fill wt       1 
-----   x  ------  x -----x  ----- x ------- x  ----------       x  ---- x P 
 AS    100     100     10         WT     LC            RRF 
 
Calculate the % content of unknown impurities by the below formula; 
AT2    WS       1         2       100       Avg.Fill wt       1 
-----   x  ------  x -----x  ----- x ------- x  ----------       x  ---- x P 
 AS    100      100     10        WT     LC            RRF 
 
Calculate the % content of Acetazolamide SR Capsule by the below formula; 
AT3    WS       1         2       100       Avg.Fill wt       1 
-----   x  ------  x -----x  ----- x ------- x  ----------       x  ---- x P 
 AS    100      100     10        WT     LC            RRF 
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Where,  
AT1 = Area of the impurity –D in the sample chromatogram 
AT2 = Area of the unknown impurity in the sample   
Chromatogram 
AS  = Average area obtained from the chromatograms of six   
replicate  
   injections of standard solution 
WS  = Weight of standard taken in mg. 
WT  = Weight of sample taken in mg. 
Avg. Fill wt = Average fill weight of Acetazoamide capsule in mg. 
LC  = Label claim in mg. 
P  = Potency of the working / reference standard  
RRF = Relative retention factor.  
 
Preparation Of Impurity Spiked Solution For Solution Stability 
 The percentage RSD of the Acetazoamide and impurities was calculated for 
the mobile phase and solution stability experiment. The solution stability of 
Acetazoamide and its impurity in the related substance method was carried out by 
living a spiked sample solution in a tightly capped volumetric flask at room 
temperature for 24 hrs. The content of impurity-D and Impurity –E was determined 
at 6hrs intervals up to the study period. The mobile phase stability was also 
investigated for 24hrs by injecting the freshly prepared sample solution for every 6 
hrs interval. The content of impurity-D and Impurity – E was determined in the test 
solution. The prepared mobile phase remain constant during the study period. 
Cumulative percentage RSD was NMT 2% for peak area of Acetazoamide in 
standard.  
 Cumulative percentage RSD was NMT 5% for peak are of known impurities 
in sample solution.  
Preparation of filter interference study solution  
Filter interference study was performed by analysis of centrifuged sample 
solution (spiked with known impurity at specification level) and sample solution 
filter to 0.45 µm nylon filter. The percentage of known impurity and total impurity 
were calculated and compare the result with centrifuged sample results.  
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Preparation of Linearity Solutions  
Linearity stock solution were prepared and inject solutions of different 
concentration of impurity –D at different linearity level ie; LOQ 25% , 50%, 75%, 
100%,125% and 150%.  
Limit of Quantification And Limit Of Detection  
The LOD and LOQ determined by signal to noise ratio method. 
LOQ level was verified by giving six replicate injections of standard solution 
containing Acetazolamide and impurity –D at about LOQ level.  
Acceptance Criteria 
Signal to noise ratio 10:1 at the level of LOQ and 2 or 3:1 at the level of LOD 
The percentage RSD for peak areas at LOQ level is not more than 10.0. 
Precision  
The precision of a method is the extent to which the individual test results of 
multiple injections of a serious of standards agree. The ICH requires precision from at 
least 6 replications to be measured at 100 percent of the test target concentration or 
from at least 9 replications covering the complete specified range. For example, the 
results can be obtained at 3concentration with 3 injections at each concentration.  
Accuracy  
This was performed by the addition of known amounts of the formulation by 
weigh or volume to the placebo formulation working in the linear range of detection 
of the analyte. The test evaluated the specificity of the method in the presence of 
excipients under chromatographic condition used for the analysis of the formulation.  
 The accuracy was demonstrated by preparing recovery sample (spiking 
placebo with known quantities of API ) at the level of LOQ 50% ,100% ,150% of the 
targeted concentration . Prepared each level in the triplicates and the average value 
taken to calculate the recovery .The RSD of the replicates will provide the analysis 
variation or how precise the method was.  
Ruggedness 
Six samples were analyzed as per test method with the spiking of known 
impurities in the specification level with different analyst, different day, different 
instrument and different column. The percentage of known impurities and total 
impurities six samples were calculate.  
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Finally, diluted to 20mL with diluent. All the degraded samples and placebo 
were injected to the chromatographic system. 
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7. RESULTS AND DISCUSSION 
 
HPLC method development and optimization  
Selection of diluent 
Acetazolamide is readily soluble in potassium dihydrogen ortho phosphate 
buffer. So mobile phase was used as a solvent(Diluent) of choice for the drug.  
Wavelength Selection  
Standard and impurities were scanned on PDA detector between 200 to 800 
nm and 265 nm was selected as an optimum wavelength for analysis were even 
Acetazolamide and its impurities have a good response.  
Selection of Column And Column Temperature  
Experiments with different C18 columns were conducted to achieve best 
separation of analyte peak with other blank and placebo peaks. C18 columns such as 
waters x-terra C-18, inertsil C-18, waters symmetry C-18, Hypresil ODS C-18, 
Hypresil BDS C-18, synergi polar RP phenomenex C-18 etc were tried.  
 As usually initial stage column temperature is maintained at ambian and then 
increased slowly to obtain good peak shape , retention time , peak symmetry , better 
separation .  
 After reviewing the results it was found that the peak shape, retention time, 
resolution , tailing factor , column efficiency are good with synergi polar RP 
phenomenox C-18 (150 x4.6mm,4.0µm) and hence synergi polar RP phenomenox C-
18 column and column temperature 25oC was selected  
Selection of Buffer  
Ideally the strength of the buffers shall be between 0.05m to 0.20m. The 
selection of buffer and strength is done always in combination with selection of 
organic phase composition in mobile phase.  
 Experiments conducted using different buffer strength to obtain the requires 
separations of all individual impurities and degradents. The selected buffer strength 
and effect of variation studied.  
 After reviewing the results potassium dihydrogen ortho phosphate buffer is 
selected and it give better resolution than other buffers.  
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Selection of Flow Rate 
Select the flow rate which gives least retention time, good peak symmetries , 
least back pressures and better separation of impurities from each other and from API 
peak.  
 After reviewing the result it was found that the flow rate having a 1.0ml /min. 
which have given least retention time , good peak symmetry , and better separation of 
impurities from each other and from API peak. 
Selection of mobile phase composition  
 Initially experiment conducted with mobile phase having buffers with 
different pH an organic phase to check for the best separation between the impurities. 
Alternatively, solution of stressed drug substance can be used to check for separation 
of impurities.  
 After reviewing the results it was found that the mobile phase composition, 
Buffer: Acetonilitrile (900:100) had given best separation between the impurities, 
blank and placebo, so peak purity gets passed.  
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METHOD DEVELOPMENT TRIALS 
Fig-2.1 
 
Separation using Water X-terra C-18 column 
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Fig-3.3 
 
Separation using Methanol : Buffer 
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Fig-3.4 
 
Separation using Acetonitrile:Buffer (50:50) 
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Fig-4.3 
 
Separation using Acetonitrile : Buffer (900:100) at flow rate 1.2ml/min 
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METHOD VALIDATION 
PRECISION  
System Precision 
 Six replicate injections of standard solution was injected as per method. The 
mean and percentage RSD for the peak areas of Acetazolamide were calculated. The 
result are tabulated in the table below 
Acceptance Criteria 
The percentage RSD for peak area of Acetazolamide is not be more than 5.0 
System Precision Data 
TABLE-8 
S. No Peak Area 
1 59938 
2 60167 
3 60010 
4 60301 
5 60691 
6 61097 
Mean 60367 
% RSD 0.7 
 
Conclusion 
The percentage RSD value indicate an acceptable level of precision of the analytical 
system for the estimation of Acetazolamide. 
METHOD PRECISION  
 Six samples were analysed as per test method with the spiking of known 
impurities in the specification level. Percentage of known impurities and total 
impurities in six sample and percentage RSD for percentage of known impurities and 
total impurities were calculated. 
Acceptance Criteria  
 The percentage RSD for known impurities and total impurities of six sample is 
not more than 10.0  
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Method precision Chromatogram 
fig-5.0 
 
Method Precision Data 
      Impurity-D 
      TABLE-9 
S.No Peak Area % w/w 
1 48942 0.25 
2 47425 0.24 
3 49223 0.25 
4 49945 0.25 
5 49735 0.25 
6 47964 0.24 
Average 48872 0.25 
% RSD - 2.1 
Conclusion  
 The percentage RSD value indicates an acceptable level of precision of the 
analytical method for estimation of impurities  
 
 
 
 
62 
 
INTERMEDIATE PRECISION  
 Six samples were analyzed as per test method with the spiking of known 
impurity in the specifications level by different analyst, different instrument and 
different column and different day. Percentage of known impurity and total impurities 
in six samples were calculated. Over all percentage RSD for method and intermediate 
precision result calculated for known and total impurity calculated  
 
Acceptance Criteria  
 The percentage RSD for known and total impurities of six samples is not more 
than 10.0  
Standard deviation 
Percentage RSD  =        x   100 
                      Mean 
 
 The overall percentage RSD for method precision and intermediate precision 
result is not more than 10.0 for known and total impurities  
 
Intermediate Precision 
Analyst Analyst-I Analyst-II 
Name DIBIN.E M.Venkatesan 
Instrument No. QHPL4012 QHPL4013 
Column Id No. SFAD/LC/05/134 SFAD/LC/02/002 
Date 5/11/2011 5/11/2011 
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Intermediate precision chromatogram (Analyst-1) 
Fig-6.1 
 
 
 
Intermediate Precision Data (Analyst-I) 
           Impurity-D 
TABLE-10 
Sample No Peak Area % w/w 
1 53071 0.25 
2 52383 0.24 
3 52630 0.25 
4 52193 0.25 
5 52936 0.25 
6 52578 0.24 
Average 52632 0.25 
% RSD - 2.1 
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Linearity plot for Acetazolamide 
Fig-8.7 
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Linearity Data of Acetazolamide 
TABLE-14 
S.No Level (%) Concentration 
(µg/mL) 
Peak Area 
1 LOQ 0.04 2803 
2 25 % 0.20 14393 
3 50 % 0.40 28711 
4 75 % 0.60 42882 
5 100 % 0.79 57439 
6 125 % 0.99 71923 
7 150 % 1.19 86314 
Slope 72463 
y-intercept -90.34 
r-value 0.999 
RSS 57389 
 
Linearity plot for impurity – D 
Fig-8.8 
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Linearity Data of Impurity-D 
TABLE-15 
S.No Level (%) Concentration 
(µg/mL) 
Peak Area 
1 LOQ 0.04 1932 
2 25 % 0.20 9156 
3 50 % 0.39 18110 
4 75 % 0.59 27120 
5 100 % 0.78 36177 
6 125 % 0.98 45253 
7 150 % 1.17 54079 
Slope 46134 
y-intercept 115.36 
r-value 1.000 
RSS 20238 
 
Conclusion  
 The detector response of impurity – D and Acetazolamide is directly 
proportional to concentration ranging from LOQ to 150 % (with respect to 
specification limit)  
LOQ AND LOD 
The LOD and LOQ of Acetazolamide related compounds and Acetazolamide 
has been determined by signal to noise ratio. 
Acceptance Criteria  
 Signal to noise ratio 10:1 at the level of LOQ and 2 or 3 :1at the level of LOD 
. 
The percentage RSD for the peak area at LOQ level is not more than 10.0 
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Sample Solution (28hrs) 
Fig-10.5 
 
 
Sample Solution (38hrs) 
Fig-10.6 
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Solution Stability for Sample 
TABLE-16 
Sample solution 
 
Time in hours 
Ambient condition 
Peak area Cumulative % RSD 
Initial 48942 - 
7 48715 0.3 
15 49836 1.2 
28 52384 3.4 
38 52201 3.5 
48 52311 3.5 
 
Solution Stability For Standard 
TABLE-17 
Standard Solution 
Time in hours Ambient Condition 
Peak Area Cumulative % RSD 
Initial 61482 - 
2 61483 0.0 
9 62318 0.8 
17 62441 0.9 
30 67257 3.9 
40 67574 4.1 
48 66640 4.1 
 
Conclusion  
Cumulative percentage RSD is not more than 5.0 for peak area of 
Acetazolamide in standard. 
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Accuracy of Acetazolamide 
TABLE-18 
Level Sample 
No 
Amount 
added in 
µg 
Amount 
recovered 
in µg 
% 
recovery 
Mean % RSD 
LOQ 1 0.040 0.041 102.5 102.5 0.0 
2 0.040 0.041 102.5 
3 0.040 0.041 102.5 
100% 1 0.798 0.780 97.7 98.1 0.4 
2 0.798 0.782 98.0 
3 0.798 0.786 98.5 
150% 1 1.196 1.159 96.9 97.5 1.4 
2 1.196 1.155 96.6 
3 1.196 1.185 99.1 
 
Accuracy of Impurity-D 
TABLE-19 
Level Sample 
No 
Amount 
added in 
µg 
Amount 
recovered 
in µg 
% 
recovery 
Mean % RSD 
LOQ 1 0.041 0.041 100.0 99.2 1.4 
2 0.041 0.041 100.0 
3 0.041 0.040 97.6 
100% 1 0.828 0.826 99.8 102.2 0.5 
2 0.828 0.834 100.7 
3 0.828 0.835 100.8 
150% 1 1.242 1.245 100.2 100.2 0.1 
2 1.242 1.243 100.1 
3 1.242 1.246 100.3 
 
Conclusion  
 The analytical method meets the pre established acceptance criteria for 
accuracy study as per protocol. 
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Acetazolamide 
TABLE-20 
Sample No Purity Angle Purity Threshold 
Unstressed 0.042 0.266 
Acid Stressed 0.024 0.250 
Base Stressed 0.031 0.244 
Peroxide Stressed 0.040 0.254 
Thermal Stressed 0.046 0.270 
PhotoStability Controlled 0.043 0.268 
PhotoStability UnControlled 0.043 0.268 
 
Impurity-D 
TABLE-21 
Sample No Purity Angle Purity Threshold 
Unstressed 4.816 5.350 
Acid Stressed 0.073 0.264 
Base Stressed 0.239 0.278 
Peroxide Stressed 0.082 0.263 
Thermal Stressed 2.373 2.856 
PhotoStability Controlled 4.667 5.770 
PhotoStability UnControlled 5.021 5.239 
 
ROBUSTNESS 
Robustness of the method was verified by deliberately changing the following 
method conditions.  
1. Flow rate (+ 10%) 
2. Column oven temperature (+ 5 oC) 
3. Wave length (+ 2nm) 
4. Organic content in mobile phase (+ 2% absolute) 
5. PH of the mobile phase buffer (+ 0.2 units) 
System suitability was evaluated in each condition and impurity spiked sample 
was analyzed.  
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Robustness – higher organic (chromatogram) 
Fig-13.5 
 
 
 
 
 
 
 
 
 
 
 
 
ROBUSTNESS 
TABLE-22 
Sr.  No I II III 
Impurity -D Total 
impurity 
Impurity -D Total 
impurity 
Impurity -D Total 
impurity 
1 0.25 0.36 0.26 0.38 0.30 0.40 
2 0.24 0.33 0.26 0.37 0.30 0.39 
3 0.25 0.37 0.26 0.37 0.29 0.39 
4 0.25 0.37 - - - - 
5 0.25 0.36 - - - - 
6 0.24 0.35 - - - - 
Over all 
mean 
- - 0.25 0.36 0.26 
 
0.37 
Overall 
% RSD 
- - 3.1 4.1 9.7 6.0 
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ROBUSTINESS 
TABLE-23 
Sr.  No IV V VI 
Impurity -D Total 
impurity 
Impurity -D Total 
impurity 
Impurity -D Total 
impurity 
1 0.27 0.39 0.28 0.39 0.29 0.41 
2 0.27 0.39 0.28 0.42 0.29 0.41 
3 0.29 0.42 0.30 0.46 0.31 0.45 
4 - - - - - - 
5 - - - - - - 
6 - - - - - - 
Over all 
mean 
0.26 0.37 0.26 0.38 0.26 
 
0.38 
Overall 
% RSD 
6.5 7.1 7.8 9.5 9.9 9.8 
 
ROBUSTINESS 
TABLE-24 
Sr.  No IV V 
Impurity -D Total impurity Impurity -D Total 
impurity 
1 0.24 0.34 0.29 0.40 
2 0.24 0.34 0.28 0.39 
3 0.24 0.34 0.29 0.39 
4 - - - - 
5 - - - - 
6 - - - - 
Over all 
mean 
0.24 0.35 0.26 0.37 
Overall % 
RSD 
2.2 4.1 7.9 6.0 
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TABLE-25 
Note Experiment  (Actual value) 
I Method precision data 
II Wavelength (263  nm) 
III Wavelength  (267 nm) 
IV Column  oven temperature  (300C) 
V Flow rate (0.9 m L/ min) 
VI Flow rate (1.1  mL/ min) 
VII Organic content (8%) 
VIII Organic  content  (12%) 
 
Conclusion  
RRT`s of known impurity was within the limit. System suitability gets passed.  
SYSTEM SUITABILITY 
System suitability was evaluated by injecting resolution and standard solution 
during various days of validation. Resolution, symmetry factor, theoretical plate count 
and % RSD for the peak areas of Acetazolamide were verified. 
 
System Suitability Chromatogram 
Fig-14.0 
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FILTER INTERFERENCE DATA 
TABLE-27 
Filter name Pore size L.No Manufacturer 
Nylon filter 0.45µm SN3190 Advanced micro devices pvt.ltd 
 
TABLE-28 
Name Result in % w/w % difference 
Filtered sample Centrifuged sample 
Impurity-D 0.24 0.25 4.0 
 
Conclusion 
0.45µm nylon filter suitable for filtering the sample solution. 
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8. CONCLUSION 
A simple, economic, selective, precise and stability-indicating HPLC method has 
been developed and validated for analysis of Acetazolamide SR Capsules and its 
related substances. Reversed phase chromatography was performed on a C-18 column 
with Acetonitrile : Buffer as mobile phase at a flow rate of 1.0mL/min. Detection was 
performed at 265nm and a sharp peak was obtained for Acetazolamide at a retention 
time of 7.5 min. The %RSD for the peak area of LOQ level is not more than 2. The 
method was validated for accuracy, precision, reproducibility, specificity and 
robustness, in accordance with ICH guidelines. Statistical analysis proved the method 
was precise, reproducible, selective, specific, and accurate for the analysis of 
Acetazolamide SR capsules. The wide linearity range, sensitivity, accuracy, short 
retention time and simple mobile phase imply the method is suitable for routine 
quantification of Acetazolamide with high precision and accuracy. 
The proposed method can be used as alternative method to the reported ones for the 
routine determination of selected drugs under the study in bulk and pharmaceutical 
dosage forms. In RS method all the peaks were well separated, peak purity was 
passing for the peaks and finally method was a stability-indicating method. 
Thus the purpose of the present investigation was successfully achieved. 
Pharmaceutical analysis simply means analysis of pharmaceuticals. Today 
pharmaceutical analysis entails much more than the analysis of active pharmaceutical 
ingredients or the formulated product. The pharmaceutical analyst plays in a major 
rule in assuring identity, safety, efficacy, purity, and quality of a drug product. New 
methods are now being developed with a great deal of consideration to worldwide 
harmonization. As a result, new products can be assured to have comparable quality 
and can be brought to international markets faster.  
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The result of the validation parameters meet the ICH guidelines. 
S.No Parameters Limit Pass/Fail 
1 System suitability 
data 
RSD NMT 2% 
Tailing NMT 2% 
Plate count NLT 
10000 
Passes 
2 Specificity No interference 
with the retention 
time of analyte 
peak. 
Passes 
3 Precision RSD NMT 2% Passes 
4 Linearity Correlation 
coefficient NLT 
0.999 
Passes 
5 Accuracy % recovery in the 
range of 90-110% 
Passes 
6 Robustness RSD NMT 2% Passes 
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